Abstract
Bruxism is the nocturnal or diurnal repetitive activity of the masticatory muscles, which has been reported to be seen at an incidence of 20% in the population. It is a condition that negatively affects the quality of life by causing complaints such as headache, tooth clenching and, as a result, structural disorders in the teeth and wide facial pain. Many options have been used in treatment, but a special algorithm has not been defined yet. Although many options from the use of dental splint to pharmacological treatments have taken place in the literature, the rate of discontinuation of these treatments may be high due to the long-term use of these treatments. In this study, we aimed to evaluate retrospectively the efficacy of Botulinum toxin type A (Dysport® England, Ipsen), which is a well-known strong bacterial toxin and sufficient to apply twice a year on average for the treatment of bruxism.